Prevention and handling of acute allergic and infusion reactions in oncology

Annals of Oncology

Volumn 23, Issue SUPPL. 10, 2012, Pages

  Joerger, M ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Antigen antibody reaction; Chemotherapy; Drug hypersensitivity; Immediate hypersensitivity infusion therapy

Indexed keywords

ADRENALIN; ANTHRACYCLINE DERIVATIVE; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; ASPARAGINASE MACROGOL; CARBOPLATIN; CHIMERIC ANTIBODY; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DIPHENHYDRAMINE; DOPAMINE; DOXORUBICIN; ENDOXANE; EPIPODOPHYLLOTOXIN; ETOPOSIDE; HISTAMINE H1 RECEPTOR ANTAGONIST; IFOSFAMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; PLATINUM COMPLEX; PROCARBAZINE; RANITIDINE; RITUXIMAB; STEROID; TAXANE DERIVATIVE; TENIPOSIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL CRAMP; ADAPTIVE IMMUNITY; ADULT RESPIRATORY DISTRESS SYNDROME; ALLERGIC REACTION; ANAPHYLAXIS; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ANTIGEN ANTIBODY REACTION; ARTICLE; BRAIN CANCER; BRONCHOSPASM; CANCER CHEMOTHERAPY; CHILL; CONJUNCTIVITIS; CYTOKINE RELEASE; DESENSITIZATION; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; ERYTHRODERMA; FACE EDEMA; HOT FLUSH; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNE SYSTEM; INJECTION SITE PRURITUS; INJECTION SITE URTICARIA; INNATE IMMUNITY; LEUKEMIA; MACULOPAPULAR RASH; MULTIPLE CYCLE TREATMENT; OXYGEN THERAPY; PATIENT ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; PRURITUS; RASH; RIGOR; SIDE EFFECT; SKIN DISEASE; SKIN TEST; TACHYCARDIA; THORAX PAIN; TOXIC EPIDERMAL NECROLYSIS; URTICARIA;

ANAPHYLAXIS; ANTIBODIES, MONOCLONAL; ASPARAGINASE; DRUG HYPERSENSITIVITY; HUMANS; IMMUNOGLOBULIN E; NEOPLASMS; PLATINUM; PODOPHYLLOTOXIN; PROCARBAZINE; TAXOIDS;

EID: 84866766244     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds314     Document Type: Article

References (39)

1. Demoly P, Hillaire-Buys D. Classification and epidemiology of hypersensitivity drug reactions. Immunol Allergy Clin North Am 2004; 24(3): 345-356, v.
2. Demoly P. Anaphylactic reactions-value of skin and provocation tests. Toxicology 2005; 209(2): 221-223.
3. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007; 12(5): 601-609.
4. Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 2003; 24(3): 253-262.
5. Pagani M. The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization. Med Clin North Am 2010; 94(4): 835-852, xiii.
6. Markman M, Kennedy A, Webster K et al. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol 2000; 18(1): 102-105.
7. Colwell HH, Mathias SD, Ngo NH et al. The impact of infusion reactions on oncology patients and clinicians in the inpatient and outpatient practice settings: oncology nurses' perspectives. J Infus Nurs 2007; 30(3): 153-160.
8. Demoor PA, Matusov Y, Kelly C et al. A retrospective review of the frequency and nature of acute hypersensitivity reactions at a medium-sized infusion center: comparison to reported values and inconsistencies found in literature. J Cancer 2011; 2: 153-164.
9. Zanotti KM, Markman M. Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf 2001; 24(10): 767-779.
10. Polyzos A, Tsavaris N, Gogas H et al. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience. Oncology 2009; 76(1): 36-41.
11. Lee MY, Yang MH, Liu JH et al. Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication. Support Care Cancer 2007; 15(1): 89-93.
12. Syrigou E, Syrigos K, Saif MW. Hypersensitivity reactions to oxaliplatin and other antineoplastic agents. Curr Allergy Asthma Rep 2008; 8(1): 56-62.
13. Pagani M, Bonadonna P, Senna GE et al. Standardization of skin tests for diagnosis and prevention of hypersensitivity reactions to oxaliplatin. Int Arch Allergy Immunol 2008; 145(1): 54-57.
14. Bhargava P, Gammon D, McCormick MJ. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 2004; 100(1): 211-212.
15. Sliesoraitis S, Chikhale PJ. Carboplatin hypersensitivity. Int J Gynecol Cancer 2005; 15(1): 13-18.
16. Gadducci A, Tana R, Teti G et al. Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. Int J Gynecol Cancer 2008; 18(4): 615-620.
17. Markman M, Kennedy A, Webster K et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 1999; 17(4): 1141.
18. Castells MC, Tennant NM, Sloane DE et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008; 122(3): 574-580.
19. Dizon DS, Sabbatini PJ, Aghajanian C et al. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol 2002; 84(3): 378-382.
20. Basu R, Rajkumar A, Datta NR. Anaphylaxis to cisplatin following nine previous uncomplicated cycles. Int J Clin Oncol 2002; 7(6): 365-367.
21. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995; 332(15): 1004-1014.
22. Lee C, Gianos M, Klaustermeyer WB. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol 2009; 102(3): 179-187; quiz 87-9, 222.
23. Kintzel PE. Prophylaxis for paclitaxel hypersensitivity reactions. Ann Pharmacother 2001; 35(9): 1114-1117.
24. Dizon DS, Schwartz J, Rojan A et al. Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program. Gynecol Oncol 2006; 100(1): 149-151.
25. Narta UK, Kanwar SS, Azmi W. Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Crit Rev Oncol Hematol 2007; 61(3): 208-221.
26. Muller HJ, Beier R, Loning L et al. Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. Br J Haematol 2001; 114(4): 794-799.
27. Hak LJ, Relling MV, Cheng C et al. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia 2004; 18(6): 1072-1077.
28. Weiss RB. Hypersensitivity reactions. Semin Oncol 1992; 19(5): 458-477.
29. Hudson MM, Weinstein HJ, Donaldson SS et al. Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease. J Clin Oncol 1993; 11(6): 1080-1084.
30. Ozguven AA, Uysal K, Gunes D et al. Delayed renal excretion of methotrexate after a severe anaphylactic reaction to methotrexate in a child with osteosarcoma. J Pediatr Hematol Oncol 2009; 31(4): 289-291.
31. Hani N, Casper C, Groth W et al. Stevens-Johnson syndrome-like exanthema secondary to methotrexate histologically simulating acute graft-versus-host disease. Eur J Dermatol 2000; 10(7): 548-550.
32. Popescu NA, Sheehan MG, Kouides PA et al. Allergic reactions to cyclophosphamide: delayed clinical expression associated with positive immediate skin tests to drug metabolites in five patients. J Allergy Clin Immunol 1996; 97(1 Pt 1): 26-33.
33. Khaw SL, Downie PA, Waters KD et al. Adverse hypersensitivity reactions to mesna as adjunctive therapy for cyclophosphamide. Pediatr Blood Cancer 2007; 49(3): 341-343.
34. Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 2008; 13(6): 725-732.
35. Breslin S. Cytokine-release syndrome: overview and nursing implications. Clin J Oncol Nurs 2007; 11(1 Suppl): 37-42.
36. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005; 31(6): 456-473.
37. Davis TA, Grillo-Lopez AJ, White CA et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18(17): 3135-3143.
38. Vogel WH. Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs 2010; 14(2): E10-E21.
39. Lieberman P, Nicklas RA, Oppenheimer J et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol 2010; 126(3): 477-480 e1-42.